Evolving Therapies and Clinical Outcomes in the Management of Anemia in CKD

Abstract

Anaemia is a common and debilitating complication of chronic kidney disease (CKD), contributing significantly to morbidity, mortality, and reduced quality of life. Its pathophysiology is multifactorial, primarily driven by insufficient erythropoietin production, iron deficiency, and chronic inflammation. The paper aims to review evolving therapies for anaemia management in chronic kidney disease (CKD) and evaluate their clinical outcomes. Over the past decades, management strategies have evolved from traditional erythropoiesis-stimulating agents (ESAs) and iron supplementation to the emergence of novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). ESAs remain the cornerstone of therapy, effectively improving haemoglobin levels and reducing transfusion dependence. However, safety concerns regarding cardiovascular risks and potential tumour progression have prompted cautious use and exploration of alternative options. Intravenous iron formulations, including newer preparations with improved safety profiles, have enhanced iron bioavailability and reduced infusion-related adverse events. HIF-PHIs represent a major advancement by promoting endogenous erythropoietin synthesis, improving iron metabolism, and attenuating inflammation-related anaemia, with growing evidence supporting their efficacy in both dialysis and non-dialysis CKD patients. Despite these innovations, individualised treatment remains critical—balancing haemoglobin targets, iron status, comorbidities, and patient-reported outcomes. Current clinical trials are expanding the evidence base for newer agents, assessing long-term safety, cardiovascular outcomes, and quality-of-life benefits. This review summarises the evolving landscape of anaemia management in CKD, highlighting mechanisms, therapeutic efficacy, and outcome implications of traditional and emerging agents. Future directions emphasise optimising combination therapy, addressing residual risks, and developing personalised treatment algorithms that align with evolving clinical guidelines and patient-centred care. Ultimately, integrated and evidence-based anaemia management has the potential to improve survival, functional status, and overall disease prognosis in individuals living with CKD. In summary, anaemia management in CKD has evolved from a one-dimensional focus on haemoglobin correction to a multifaceted, patient-centred approach emphasising safety, physiological restoration, and quality of life.